TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or dec...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Bejar, Rafael, Lord, Allegra, Stevenson, Kristen, Bar-Natan, Michal, Pérez-Ladaga, Albert, Zaneveld, Jacques, Wang, Hui, Caughey, Bennett, Stojanov, Petar, Getz, Gad, Garcia-Manero, Guillermo, Kantarjian, Hagop, Chen, Rui, Stone, Richard M., Neuberg, Donna, Steensma, David P., Ebert, Benjamin L.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2014
主題:
Myeloid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4208285/
https://ncbi.nlm.nih.gov/pubmed/25224413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-582809
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍